Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes
The DOI matches its Crossref record.
Abstract
Glucagon-like peptide 1 (GLP-1) was discovered as an incretin (insulinotropic gut) hormone. Biological actions of GLP-1 in healthy and type 2 diabetic subjects include (a) stimulation of insulin secretion in a glucose-dependent manner, (b) suppression of glucagon, (c) reduction in appetite and food intake, (d) deceleration of gastric emptying. In animal experiments, in addition, (e) stimulation of beta-cell neogenesis, growth and differentiation in animal and tissue culture experiments, and (f) in vitro inhibition of beta-cell apoptosis induced by different agents have been observed. Since the incretin effect--the higher insulin secretory response to oral as compared to intravenous glucose loads - is reduced in patients with Type 2 diabetes, GLP-1 has been used to pharmacologically replace incretin. Intravenous GLP-1 can normalise, and subcutaneous GLP-1 can significantly lower plasma glucose in the majority of patients with Type 2 diabetes. The magnitude of this effect does not greatly depend on patient characteristics such as age, sex, obesity, or baseline insulin and glucagon, with minor influences of previous antidiabetic therapy and actual metabolic control. GLP-1 itself, however, is inactivated rapidly in vivo by the protease DPP IV and can only be used for short-term metabolic control, such as in intensive care units (potentially useful in patients with acute myocardial infarction, coronary surgery, cerebrovascular events, septicaemia, during the perioperative period and while on parenteral nutrition). For more long-term metabolic control, incretin mimetics (agonists at the GLP-1 receptor) with more favourable pharmacokinetic profiles should be used.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [140]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [140]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [140]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [140]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [140]
Citations
Cites
Still being checked.
Cited by
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Self-citationGejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297
“Nausea 1 (7) 2 (15) 0 (0) Hypoglycemia 2 (14) 2 (15) 0 (0) Fehse et al.”
Self-citationTumminia, A., Vinciguerra, F., Parisi, M., & Frittitta, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113306 · Cited by 249
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Relationship Between β-Cell Mass and Fasting Blood Glucose Concentration in Humans
Ritzel, R. A., Butler, A. E., Rizza, R. A., Veldhuis, J. D., & Butler, P. C. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1538 · Cited by 197
“Several therapeutic strategies are now being proposed that may reverse the defect in -cell mass in people with type 2 diabetes, for example glucagon-like peptide 1 or glucagon-like peptide 1–like surrogates (5).”
BackgroundInhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
Pratley, R. E., & Salsali, A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162746 · Cited by 195
Pratley, R., Jauffret-Kamel, S., Galbreath, E., & Holmes, D. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-944546 · Cited by 194
Patriti, A., Aisa, M. C., Annetti, C., Sidoni, A., Galli, F., Ferri, I., Gullà, N., & Donini, A. (2007) · Surgery · doi:10.1016/j.surg.2007.03.001 · Cited by 170
Alter, M. L., Ott, I. M., von Websky, K., Tsuprykov, O., Sharkovska, Y., Krause-Relle, K., Raila, J., Henze, A., Klein, T., & Hocher, B. (2012) · Kidney and Blood Pressure Research · doi:10.1159/000341487 · Cited by 151
Mack, C. M., Moore, C. X., Jodka, C. M., Bhavsar, S., Wilson, J. K., Hoyt, J. A., Roan, J. L., Vu, C., Laugero, K. D., Parkes, D. G., et al. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803284 · Cited by 150
Paraneoplastic syndromes secondary to neuroendocrine tumours
Kaltsas, G., Androulakis, I. I., de Herder, W. W., & Grossman, A. B. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0024 · Cited by 118
ß‐cell function and anti‐diabetic pharmacotherapy
Prato, S. D., Bianchi, C., & Marchetti, P. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.770 · Cited by 107
Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration
Gedulin, B. R., Smith, P., Jodka, C. M., Chen, K., Bhavsar, S., Nielsen, L. L., Parkes, D. G., & Young, A. A. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.01.015 · Cited by 96
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Egefjord, L., Gejl, M., Møller, A., Brændgaard, H., Gottrup, H., Antropova, O., Møller, N., Poulsen, H. E., GJEDDE, A. H., Brock, B., et al. (2012) · PubMed · Cited by 91
Vilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 81
Kumar, M., Hunag, Y. P., Glinka, Y., Prud’homme, G. J., & Wang, Q. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302836 · Cited by 72
Kristensen, J., Mortensen, U. M., Schmidt, M., Nielsen, P. H., Nielsen, T. T., & Maeng, M. (2009) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-9-31 · Cited by 71
Type 2 Diabetes (T2DM) and Parkinson’s Disease (PD): a Mechanistic Approach
Sabari, S. S., Balasubramani, K., Iyer, M., Babu, H. W. S., Venkatesan, D., Gopalakrishnan, A. V., Narayanaswamy, A., Kumar, N. S., & Vellingiri, B. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03359-y · Cited by 68
He, Y., Sabo, R., Campestrini, J., Wang, Y., Rivière, G., Nielsen, J. C., Rosenberg, M. A., Ligueros‐Saylan, M., Howard, D., & Dole, W. P. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03031.x · Cited by 65
Soltani, N., Kumar, M., Glinka, Y., Prud’homme, G. J., & Wang, Q. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302944 · Cited by 65
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
Deacon, C. F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.4.533 · Cited by 59
Li, Y., Wang, Y., Wei, Q., Zheng, X., Tang, L., Kong, D., & Gong, M. (2015) · Scientific Reports · doi:10.1038/srep18039 · Cited by 48
Campbell, R. K. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h459 · Cited by 44
Lipš, M., Mráz, M., Kloučková, J., Kopecký, P., Dobiáš, M., Křížová, J., Lindner, J., Diamant, M., & Haluzík, M. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13029 · Cited by 39
“Glucagon-like peptide-1 (GLP-1) receptor agonists are a recently established class of antidiabetic drugs based on the restoration of the incretin effect.(1) In addition to improved blood glucose and body weight, experimental and clinical data have pointed to the existence of cardioprotective effects associated with ac…”
BackgroundLi, H., Zhu, H., Ge, T., Wang, Z., & Zhang, C. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10139-5 · Cited by 37
Biological activity of AC3174, a peptide analog of exendin-4
Hargrove, D. M., Kendall, E. S., Reynolds, J. M., Lwin, A. N., Herich, J. P., Smith, P., Gedulin, B. R., Flanagan, S. D., Jodka, C. M., Hoyt, J. A., et al. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.021 · Cited by 35
Fleming, A., & Rosenberg, L. C. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100214 · Cited by 34
The role of Islet Neogenesis-Associated Protein (INGAP) in islet neogenesis
Lipsett, M. A., Hanley, S. C., Castellarin, M. L., Austin, E. B., Suarez‐Pinzon, W. L., Rabinovitch, A., & Rosenberg, L. C. (2007) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-007-0028-3 · Cited by 33
Ding, L., Houben, T., Oligschlaeger, Y., Bitorina, A. V., Verwer, B. J., Tushuizen, M. E., & Shiri‐Sverdlov, R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.575070 · Cited by 31
Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus
Canpolat, A. G., & Şahin, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_516 · Cited by 29
Lerche, S., Soendergaard, L., Rungby, J., Moeller, N., Holst, J. J., Schmitz, O. E., & Brock, B. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03510.x · Cited by 26
Therapeutic approaches based on beta-cell mass preservation and/or regeneration
Robert, A. R. (2009) · Frontiers in bioscience · doi:10.2741/3345 · Cited by 26
Bi, Z., Wang, L., & Wang, W. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/161734 · Cited by 21
Intron 1 sequences are required for pancreatic expression of the human proglucagon gene
Zhou, L. J., Nian, M., Gu, J., & Irwin, D. M. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00596.2005 · Cited by 21
Ahmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 18
Effect of chitosan on physicochemical properties of exenatide-loaded PLGA nanoparticles
Park, M.-H., Baek, J.-S., Lee, C.-A., & Cho, C. (2013) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-013-0094-z · Cited by 17
Devitt, A. A., Williams, J. A. S., Choe, Y. S., Hustead, D. S., & Mustad, V. A. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.49a001 · Cited by 17
Gok, A. F. K., Sönmez, R. E., Kantarcı, T. R., Bayraktar, A., Emiroğlu, S., İlhan, M., & Güloğlu, R. (2019) · Turkish Journal of Trauma and Emergency Surgery · doi:10.14744/tjtes.2019.24557 · Cited by 15
Discovery of long-acting N-(cyanomethyl)-N-alkyl-l-prolinamide inhibitors of dipeptidyl peptidase IV
Kondo, T., Nekado, T., Sugimoto, I., Ochi, K., Takai, S., Kinoshita, A., Hatayama, A., Yamamoto, S., Kawabata, K., Nakai, H., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.005 · Cited by 15
Chen, W., Yan, Z., Liu, S., Zhang, G., Sun, D., & Hu, S. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1606-7 · Cited by 14
Foschi, D., Rizzi, A., Tubazio, I., Conti, L., Vago, T., Bevilacqua, M. T., Magni, A., & Puppo, M. D. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.10.025 · Cited by 13
Insulin, Brain, Alzheimer’s Disease: New Evidence
Bulgakova, S. V., Иванович, Р. П., & Treneva, E. V. (2020) · Bulletin of Science and Practice · doi:10.33619/2414-2948/52/10 · Cited by 12
Investigation of Transport Mechanism of Exendin-4 across Madin Darby Canine Kidney Cell Monolayers
Wang, M., Sun, B., Jiao, F., Zhang, H., Liu, B., Li, C., Chen, Y., Zhang, Y., & Kong, W. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.35.745 · Cited by 10
Incretin-based therapy for diabetic ulcers: from bench to bedside
Ku, H.-C., & Liang, Y. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1548607 · Cited by 9
Krishnan, A., Suryanarayanan, S., & Mansi, I. A. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241266773 · Cited by 9
Stem cells therapy for diabetes: from past to future
Li, Y., He, C., Liu, R., Xiao, Z., & Sun, B. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.04.012 · Cited by 9
Alshehri, F. S. (2025) · Medicine · doi:10.1097/md.0000000000044917 · Cited by 8
Biological activity of EXf, a peptide analogue of exendin-4
Song, G., Huan, Y., Sun, S., Chen, Y.-T., Liu, Q., & Shen, Z. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.021 · Cited by 8
The Effect of Type-2 Diabetes on Cognitive Status and the Role of Anti-diabetes Medications
Alkasabera, A., Onyali, C. B., Anim-Koranteng, C., Shah, H. E., Ethirajulu, A., Bhawnani, N., & Mostafa, J. A. (2021) · Cureus · doi:10.7759/cureus.19176 · Cited by 8
Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes
Nauck, M. A. (2005) · Practical Diabetes · doi:10.1002/pdi.801 · Cited by 8
Self-citationRungby, J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902953707 · Cited by 6
Raghavan, V. A., & Garber, A. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_7 · Cited by 5
Rajput, T. A., Yousaf, M. J., Naveed, A. K., Khan, S., & Azeem, Z. (2014) · Cited by 4
Camacho-Ramírez, A. (2015) · RODIN (Universidad de Cádiz) · Cited by 4
Sangsuriyothai, P., Watari, I., Serirukchutarungsee, S., Satrawaha, S., Podyma‐Inoue, K. A., & Ono, T. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1357730 · Cited by 3
Vineetha, K. K., Rao, G. M., Prabhu, K. A., Vinodchandran, V., Kavyashree, K., Marathe, A., & Blossom, V. (2021) · Biomedicine · doi:10.51248/.v41i2.782 · Cited by 3
Avances en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular
Pi-Sunyer, X. (2008) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(08)73556-8 · Cited by 3
Vlasakakis, G., Johnson, S. L., Lin, J., Yao, X., Gruenloh, C. J., Chism, J. P., & Nunez, D. J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0222-4 · Cited by 2
Lee, C., Lai, C.-W., Wu, G.-L., Yen, S., Huang, C., Liu, Z.-H., Hu, P.-C., & Liao, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1621448 · Cited by 2
Glucagon-like peptide-1 analogs for Alzheimer’s disease -- A systematic meta-analysis
Wang, C., & Ye, K. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/32/20240813 · Cited by 1
Mkrtumyan, A. M., & Biryukova, E. V. (2006) · Diabetes Mellitus · doi:10.14341/2072-0351-6117 · Cited by 1
Once-Weekly Glucose-Lowering Therapy for Type 2 Diabetes
LaRue, S., DeYoung, M. B., Blickensderfer, A., & Chen, S. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.3.95 · Cited by 1
Höfer, M. (2007) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.6712 · Cited by 1
Picoche, A. (2010) · Publications Et Travaux Academiques de Lorraine (Universite de Lorraine) · Cited by 1
Advances in the Treatment of Type 2 Diabetes and Cardiovascular Disease
Pi-Sunyer, X. (2008) · Revista Española de Cardiología
Gonçalves, C. G. (2010) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Obesity, Nutrigenomics, Metabolic Syndrome, and Type 2 Diabetes
Heber, D. (2007) · Oxidative stress and disease · doi:10.1201/9781420043792.ch7
Incretin-based treatment of diabetes and cardiovascular complications
Haluzík, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.012
Gajjar, A. K., & Pathak, C. D. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220103124013
(2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000202323.44809.4f
Recent advances in natural antidiabetics
Anand, A., Manjula, S. N., & Kenganora, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30086-8.00004-8
Adhikari, A. (2023) · eCommons (Cornell University) · doi:10.7298/a34n-gj81
Peng, G., Wang, C., Zhang, H.-W., Xu, T., & Di, J. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261467887
Naveed, A. K., Yousaf, M. J., Khan, S., Ahmed, T., & Shah, S. Z. (2014) · Pakistan Armed Forces Medical Journal
Sangsuriyothai, P., Watari, I., Serirukchutarungsee, S., Satrawaha, S., Podyma-Inoue, K. A., & Ono, T. (2024) · doi:10.3389/fphys.2024.1357730.s001
Metadata
- Authors
- Nauck, M. A.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Nauck, M. A.
- ORCID
- Nauck, M. A.
- Venue
- Hormone and Metabolic Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 2004-11
- Volume
- 36
- Issue
- 11/12
- Pages
- 852-858
- ISSN
- 0018-5043 (ISSN-L)
- 1439-4286
- OpenAlex
- W2084139518
- Cited by
- 72
- References
- 0
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 4
- FWCI
- 4.75
- Type
- journal article
- Language
- de
- Open access
- closed
- Locations
- Hormone and Metabolic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, type 2 diabetes, incretin-based therapy, GLP-1 receptor agonists, insulin secretion, glucagon suppression, appetite suppression, gastric emptying, beta-cell neogenesis, beta-cell apoptosis, dipeptidyl peptidase IV, plasma glucose control, intensive care, perioperative care, parenteral nutrition
- MeSH terms
- Administration, Oral, Animals, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Glucagon, Humans, Hypoglycemic Agents, Infusions, Intravenous, Insulin, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.